Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Related Articles by Review for PubMed (Select 22387003)

1.

New insights into chronic inflammation-induced immunosuppression.

Kanterman J, Sade-Feldman M, Baniyash M.

Semin Cancer Biol. 2012 Aug;22(4):307-18. doi: 10.1016/j.semcancer.2012.02.008. Epub 2012 Feb 24. Review.

PMID:
22387003
2.

Melanoma-induced immunosuppression and its neutralization.

Umansky V, Sevko A.

Semin Cancer Biol. 2012 Aug;22(4):319-26. doi: 10.1016/j.semcancer.2012.02.003. Epub 2012 Feb 13. Review.

PMID:
22349515
3.

Myeloid-derived suppressor cell role in tumor-related inflammation.

Dolcetti L, Marigo I, Mantelli B, Peranzoni E, Zanovello P, Bronte V.

Cancer Lett. 2008 Aug 28;267(2):216-25. doi: 10.1016/j.canlet.2008.03.012. Epub 2008 Apr 22. Review.

PMID:
18433992
4.

Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.

Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK.

Semin Cancer Biol. 2012 Aug;22(4):275-81. doi: 10.1016/j.semcancer.2012.01.011. Epub 2012 Feb 1. Review.

5.

Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators.

Ben-Baruch A.

Semin Cancer Biol. 2006 Feb;16(1):38-52. Epub 2005 Aug 31. Review.

PMID:
16139507
6.

Improving cancer immunotherapy by targeting tumor-induced immune suppression.

Stewart TJ, Smyth MJ.

Cancer Metastasis Rev. 2011 Mar;30(1):125-40. doi: 10.1007/s10555-011-9280-5. Review.

PMID:
21249424
7.

Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Coussens LM, Zitvogel L, Palucka AK.

Science. 2013 Jan 18;339(6117):286-91. doi: 10.1126/science.1232227. Review. Erratum in: Science. 2013 Mar 29;339(6127):1522.

8.

The inflammatory tumor microenvironment and its impact on cancer development.

de Visser KE, Coussens LM.

Contrib Microbiol. 2006;13:118-37. Review.

PMID:
16627962
9.

Targeting the immune system in cancer.

Chaudhuri D, Suriano R, Mittelman A, Tiwari RK.

Curr Pharm Biotechnol. 2009 Feb;10(2):166-84. Review.

PMID:
19199949
10.

Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells.

Hurwitz AA, Watkins SK.

Cancer Immunol Immunother. 2012 Feb;61(2):289-93. doi: 10.1007/s00262-011-1181-5. Epub 2012 Jan 12. Review.

PMID:
22237887
11.

Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients.

Filipazzi P, Huber V, Rivoltini L.

Cancer Immunol Immunother. 2012 Feb;61(2):255-63. doi: 10.1007/s00262-011-1161-9. Epub 2011 Nov 27. Review.

PMID:
22120756
12.
13.

Immunotherapeutic modulation of the suppressive liver and tumor microenvironments.

Chan T, Wiltrout RH, Weiss JM.

Int Immunopharmacol. 2011 Jul;11(7):879-89. doi: 10.1016/j.intimp.2010.12.024. Epub 2011 Jan 15. Review.

14.

Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells.

Bianchi G, Borgonovo G, Pistoia V, Raffaghello L.

Histol Histopathol. 2011 Jul;26(7):941-51. Review.

PMID:
21630223
15.

[Immune response and cancer].

El Hage F, Abouzahr-Rifai S, Meslin F, Mami-Chouaib F, Chouaib S.

Bull Cancer. 2008 Jan;95(1):57-67. doi: 10.1684/bdc.2008.0558. Review. French.

PMID:
18230571
16.

Camouflage and sabotage: tumor escape from the immune system.

Poschke I, Mougiakakos D, Kiessling R.

Cancer Immunol Immunother. 2011 Aug;60(8):1161-71. doi: 10.1007/s00262-011-1012-8. Epub 2011 Apr 6. Review.

PMID:
21626032
17.

Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly.

Serafini P.

Immunol Res. 2013 Dec;57(1-3):172-84. doi: 10.1007/s12026-013-8455-2. Review.

PMID:
24203443
18.

Chronic inflammation and cancer: suppressing the suppressors.

Baniyash M, Sade-Feldman M, Kanterman J.

Cancer Immunol Immunother. 2014 Jan;63(1):11-20. doi: 10.1007/s00262-013-1468-9. Epub 2013 Aug 29. Review.

PMID:
23990173
19.

Unresolved inflammation: 'immune tsunami' or erosion of integrity in immune-privileged and immune-responsive tissues and acute and chronic inflammatory diseases or cancer.

Khatami M.

Expert Opin Biol Ther. 2011 Nov;11(11):1419-32. doi: 10.1517/14712598.2011.592826. Epub 2011 Jun 11. Review.

PMID:
21663532
20.

Tumor-host immune interactions and dendritic cell dysfunction.

Yang L, Carbone DP.

Adv Cancer Res. 2004;92:13-27. Review.

PMID:
15530555
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk